Case Report Sodium Glucose Cotransporter 2 Inhibition Combined With Cetuximab Signiﬁcantly Reduced Tumor Size and Carcinoembryonic Antigen Level in Colon Cancer Metastatic to Liver 1,2 2 3 2 Junichi Okada, Shunichi Matsumoto, Kyoichi Kaira, Tsugumichi Saito, 2 4 5 6 Eijiro Yamada, Hideaki Yokoo, Ryuji Katoh, Motoyasu Kusano, 2 2 Shuichi Okada, Masanobu Yamada Clinical Clinical Practice Practice Points Points A 69-year-old male patient had been regularly visiting His cancer cells had become resistant to 2 combina- our hospital to manage his sigmoid colon cancer with tion chemotherapy regimens; thus, monotherapy with multiple liver metastases since he had undergone cetuximab was started. resection of primary sigmoid colon cancer at age 64 With the latter regimen, his glucose metabolism years. remained stable with daily oral absorption of He developed postprandial hyperglycemia from ste- dapagliﬂozin. roid administration during chemotherapy and was One month later, his carcinoembryonic antigen level referred to our outpatient clinic. had decreased dramatically from 1104 to 112.4 ng/mL, Because he was already receiving insulin therapy, we and computed tomography showed that his metastatic adjusted his insulin dosage and added a sodium glucose tumor lesions had shrunk substantially, suggesting the cotransporter (SGLT2) inhibitor (dapagliﬂozin; 5 mg/day).
Clinical Colorectal Cancer – Elsevier
Published: Mar 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera